全文获取类型
收费全文 | 185508篇 |
免费 | 12726篇 |
国内免费 | 736篇 |
专业分类
耳鼻咽喉 | 2549篇 |
儿科学 | 5084篇 |
妇产科学 | 3536篇 |
基础医学 | 23966篇 |
口腔科学 | 4073篇 |
临床医学 | 18330篇 |
内科学 | 39050篇 |
皮肤病学 | 2921篇 |
神经病学 | 18491篇 |
特种医学 | 6458篇 |
外国民族医学 | 13篇 |
外科学 | 27365篇 |
综合类 | 2671篇 |
现状与发展 | 3篇 |
一般理论 | 202篇 |
预防医学 | 14423篇 |
眼科学 | 5012篇 |
药学 | 12256篇 |
中国医学 | 238篇 |
肿瘤学 | 12329篇 |
出版年
2023年 | 661篇 |
2022年 | 552篇 |
2021年 | 2963篇 |
2020年 | 1827篇 |
2019年 | 2994篇 |
2018年 | 3502篇 |
2017年 | 2552篇 |
2016年 | 2970篇 |
2015年 | 3594篇 |
2014年 | 5272篇 |
2013年 | 8142篇 |
2012年 | 11688篇 |
2011年 | 12615篇 |
2010年 | 7090篇 |
2009年 | 6478篇 |
2008年 | 11815篇 |
2007年 | 12608篇 |
2006年 | 12129篇 |
2005年 | 12516篇 |
2004年 | 11970篇 |
2003年 | 11405篇 |
2002年 | 11068篇 |
2001年 | 1901篇 |
2000年 | 1485篇 |
1999年 | 1899篇 |
1998年 | 2494篇 |
1997年 | 2191篇 |
1996年 | 1805篇 |
1995年 | 1668篇 |
1994年 | 1513篇 |
1993年 | 1455篇 |
1992年 | 1181篇 |
1991年 | 1127篇 |
1990年 | 1035篇 |
1989年 | 991篇 |
1988年 | 970篇 |
1987年 | 865篇 |
1986年 | 981篇 |
1985年 | 1031篇 |
1984年 | 1300篇 |
1983年 | 1242篇 |
1982年 | 1668篇 |
1981年 | 1528篇 |
1980年 | 1408篇 |
1979年 | 836篇 |
1978年 | 949篇 |
1977年 | 819篇 |
1976年 | 741篇 |
1975年 | 605篇 |
1974年 | 636篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
991.
Chy-3 mice are Vegfc haploinsufficient and exhibit defective dermal superficial to deep lymphatic transition and dermal lymphatic hypoplasia. 总被引:1,自引:0,他引:1
Michael T Dellinger Robert J Hunter Michael J Bernas Marlys H Witte Robert P Erickson 《Developmental dynamics》2007,236(8):2346-2355
Recent advances in molecular lymphology and lymphatic phenotyping techniques in small animals offer new opportunities to delineate mutant mouse models. Chy-3 mutant mice were originally named for their chylous ascites, but the underlying lymphatic disorder was not defined. We now re-examined these mice and applied advanced genotyping and lymphatic phenotyping techniques to pinpoint the specific lymphatic defect in this mouse model. We demonstrated that Chy-3 mice carry a large chromosomal deletion that includes Vegfc and narrowed this region by monitoring the heterozygosity of genetic markers. We found that Chy-3 mice not only exhibited chylous ascites but also lymphedema of the hind paws and, in approximately half of the males, lymphedema of the penis. Visual lymphangiography and immunofluorescence staining showed a hypoplastic dermal lymphatic network, whereas the blood vasculature appeared unaffected. This hypoplastic lymphatic network was functional, and all adult Chy-3 mice exhibited a lateral lymphatic pathway directly connecting the inguinal to the axillary lymph node. The dermal superficial to deep lymphatic connections in upper limbs and in all cervical regions were intact and functionally drained the upper body. Lymphatic tracer was not transported from the dermal to the deep truncal lymphatic system in the lower limbs, even though the deep lymphatic vessels and nodes were present and patent. These findings further delineate the lymphatic phenotype of Chy-3 mice, identify a collateral lymph drainage pathway previously undescribed in other genetic models of lymphedema, and demonstrate a predilection for lymphatic abnormalities of the lower limbs. 相似文献
992.
993.
994.
995.
Balance and recovery from a perturbation are impaired in people with functional ankle instability. 总被引:1,自引:0,他引:1
Claire E Hiller Kathryn M Refshauge Robert D Herbert Sharon L Kilbreath 《Clinical journal of sport medicine》2007,17(4):269-275
OBJECTIVE: To determine if differences in balance and recovery would be found between controls and participants with unilateral or bilateral functional ankle instability (FAI). DESIGN: Cross-Sectional Study. SETTING: University laboratory and Community premises. PARTICIPANTS: Twenty healthy participants(C), 19 participants with unilateral FAI [both the uninjured (UC) and unstable ankle (UI) were included] and 22 participants with bilateral FAI (BI). MAIN OUTCOME MEASURES: Balance was measured in single leg stance as: number of part foot lifts in 30 s; magnitude of medio-lateral ankle movement in two foot positions; and ability to balance on the ball of the foot. Recovery was determined by time to return to baseline medio-lateral ankle movement after a 15 degree inversion perturbation. RESULTS: The controls lifted the foot fewer times than the other three groups [C = 12.7 +/- 1.8 (mean +/- SE) foot lifts, UC = 22.9 +/- 2.5, UI = 25.1 +/- 2.3, and BI = 21.1 +/- 2.2, t-test, P = 0.006] and recovered significantly faster than the unstable ankles [C = 1.53 +/- 0.42 sec (median +/- SE), UI = 2.34 +/- 0.30 sec, BI = 2.15 +/- 0.70 sec, P < 0.02]. With FAI measured by the Cumberland Ankle Instability Tool, the external control group balanced on demi-pointe better than both instability groups (P < 0.05), and recovered quicker than all groups. CONCLUSION: There are differences in balance and recovery between external controls and participants with both unilateral and bilateral FAI but not between the legs of participants with unilateral FAI. 相似文献
996.
997.
Handling of asymmetrical dimethylarginine and symmetrical dimethylarginine by the rat kidney under basal conditions and during endotoxaemia. 总被引:2,自引:0,他引:2
Robert J Nijveldt Tom Teerlink Coen van Guldener Hubert A Prins Antonie A van Lambalgen Coen D A Stehouwer Jan A Rauwerda Paul A M van Leeuwen 《Nephrology, dialysis, transplantation》2003,18(12):2542-2550
BACKGROUND: Asymmetrical dimethylarginine (ADMA) is capable of inhibiting nitric oxide synthase enzymes, whereas symmetrical dimethylarginine (SDMA) competes with arginine transport. The potential role of inflammation in the metabolism of ADMA has been elucidated in an in vitro model using tumour necrosis factor-alpha, resulting in a decreased activity of the ADMA-degrading enzyme dimethylarginine dimethylaminohydrolase (DDAH). The kidney probably plays a crucial role in the metabolism of ADMA by both urinary excretion and degradation by DDAH. We aimed to further elucidate the role of the kidney in a rat model under basal conditions and during endotoxaemia. METHODS: Twenty-five male Wistar rats weighing 275-300 g were used for this study. The combination of arteriovenous concentration differences and kidney blood flow allowed calculation of net organ fluxes. Blood flow was measured using radiolabelled microspheres according to the reference sample method. Concentrations of ADMA, SDMA and arginine were measured by high-performance liquid chromatography. RESULTS: The kidney showed net uptake of both ADMA and SDMA and fractional extraction rates were 35% and 31%, respectively. Endotoxaemia resulted in a lower systemic ADMA concentration (P = 0.01), which was not explained by an increased net renal uptake. Systemic SDMA concentrations increased during endotoxaemia (P = 0.007), which was accompanied by increased creatinine concentrations. CONCLUSIONS: The rat kidney plays a crucial role in the regulation of concentrations of dimethylarginines, as both ADMA and SDMA were eliminated from the systemic circulation in substantial amounts. Furthermore, evidence for the role of endotoxaemia in the metabolism of dimethylarginines was obtained as plasma levels of ADMA were significantly lower in endotoxaemic rats. 相似文献
998.
Shahid Hussain Darren E Dreyfus Richard J Marcus Robert W W Biederman Rita L McGill 《Nephrology, dialysis, transplantation》2003,18(11):2364-2368
BACKGROUND: Spironolactone is useful in heart failure, but is not given to dialysis patients for fear of hyperkalaemia. This study evaluated the safety of spironolactone administration in haemodialysis patients. METHODS: Fifteen haemodialysis outpatients with mean serum potassium <5.6 mEq/l over the preceding 4 months were treated with spironolactone 25 mg daily for 28 days. Serum potassium was measured before every haemodialysis during the study. Aldosterone and renin were measured at the beginning and end of the study. Patients were monitored for side effects. Data were examined with a paired t-test, with patients serving as their own controls and P < 0.05 considered significant. A sample size of 14 was required to achieve a power of 0.8 and a P = 0.05 to detect a potassium difference of 0.5 +/- 0.6 mEq/l. All patients were analysed as intention-to-treat. RESULTS: The mean potassium level was 4.6 +/- 0.6 mEq/l at baseline and 4.9 +/- 0.9 mEq/l at study completion (P = 0.14). Thirteen patients completed the trial with no potassium levels >6.0 mEq/l. Four patients had potassium levels between 5.5 and 6.0 mEq/l. One patient was withdrawn at day 20 after developing hyperkalaemia (7.6 mEq/l). Another patient was withdrawn at day 25 after missing a dialysis treatment. There were no differences in either baseline or 28 day aldosterone or renin levels (16.8 +/- 28.8 vs 11.7 +/- 6.1 ng/dl and 3.5 +/- 3.9 vs 3.5 +/- 3.5 ng/ml/h, respectively). Infrequent side effects included dry mouth, nosebleed, pruritis, gynecomastia and diarrhoea. No significant leukopenia or anaemia was noted. CONCLUSIONS: Spironolactone may be considered as a treatment option for selected chronic haemodialysis patients with heart disease. 相似文献
999.
Daniel Einhorn Vanita R Aroda Robert R Henry 《Endocrinology & Metabolism Clinics of North America》2004,33(3):595-616, vii-viii
Thiazolidinediones (glitazones) are the only compounds currently available that specifically target tissue insulin resistance. The two currently available drugs in this class, pioglitazone and rosiglitazone,are approved by the Food and Drug Administration for the treatment of type 2 diabetes mellitus only. The therapeutic potential of the glitazones for other consequences of insulin resistance has stirred considerable interest, especially with regard to their potential beneficial impact on atherosclerotic cardiovascular disease and diabetes prevention. They also have been considered in the management of polycystic ovarian syndrome, nonalcoholic fatty liver disease, and other consequences of insulin resistance. The nonglycemic potential of glitazones is a clinical area in rapid evolution, wherein most data are on the impact of the glitazones onsurrogate markers that are associated with diseases, not on disease outcomes. This article provides insight and guidance to clinicians on the diverse nonglycemic potential of glitazones until conclusive outcome data become available. 相似文献
1000.